Literature DB >> 26482407

The effect of chorionic villus sampling on the fraction of cell-free fetal DNA in maternal plasma.

Amber R Samuel1, Moeun Son2, Cande V Ananth1,3, Ronald J Wapner1.   

Abstract

OBJECTIVE: This study aims to assess whether the fraction of cell-free fetal DNA (cffDNA) is different at 24 h or 7 days after chorionic villus sampling (CVS), compared to subjects that do not undergo CVS.
METHODS: Pregnant women undergoing CVS for genetic testing and matched subjects undergoing first trimester combined screening alone were enrolled between 11(0/7) and 13(6/7) weeks gestation. The fractions of cffDNA were compared before the procedure, 24 h after and 7 days after between CVS patients and ultrasound-only patients.
RESULTS: Forty-five women underwent CVS and 45 had ultrasound alone. The women undergoing CVS were, on average, older (36.8 years versus 28.5 years, p=0.001) and had a higher baseline fraction of cffDNA than women in the comparison group (11.4% versus 9.8%, p=0.033). Both groups had a decrease in the mean fraction of cffDNA after 24 h. After 7 days, the trend of the mean fraction of cffDNA continued to decline in the CVS group but began to trend toward an increase in the ultrasound only group.
CONCLUSIONS: CVS does not significantly increase the fraction of cell free fetal (placental) DNA in the maternal plasma. A downward trend in cffDNA in maternal plasma is seen at 24 h and 7 days following CVS compared to baseline.

Entities:  

Keywords:  Cell-free fetal DNA; chorionic villus sampling; fetal fraction

Mesh:

Substances:

Year:  2015        PMID: 26482407     DOI: 10.3109/14767058.2015.1095885

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  4 in total

Review 1.  Overview and recent developments in cell-based noninvasive prenatal testing.

Authors:  Liesbeth Vossaert; Imen Chakchouk; Roni Zemet; Ignatia B Van den Veyver
Journal:  Prenat Diagn       Date:  2021-05-18       Impact factor: 3.242

2.  Clinical performance of non-invasive prenatal served as a first-tier screening test for trisomy 21, 18, 13 and sex chromosome aneuploidy in a pilot city in China.

Authors:  Yanhui Liu; Hailiang Liu; Yi He; Wanfang Xu; Qiulin Ma; Yuzhen He; Wei Lei; Guoquan Chen; Zheng He; Jiayi Huang; Jianan Liu; Yuanru Liu; Quanfei Huang; Fubing Yu
Journal:  Hum Genomics       Date:  2020-06-05       Impact factor: 4.639

3.  Clinical validation of a novel automated cell-free DNA screening assay for trisomies 21, 13, and 18 in maternal plasma.

Authors:  Olle Ericsson; Tarja Ahola; Fredrik Dahl; Filip Karlsson; Fredrik Persson; Olof Karlberg; Fredrik Roos; Ida Alftrén; Björn Andersson; Emelie Barkenäs; Ani Boghos; Birgit Brandner; Jenny Dahlberg; Per-Ola Forsgren; Niels Francois; Anna Gousseva; Faizan Hakamali; Åsa Janfalk-Carlsson; Henrik Johansson; Johanna Lundgren; Atefeh Mohsenchian; Linus Olausson; Simon Olofsson; Atif Qureshi; Björn Skarpås; Peter Svahn; Anna Sävneby; Eva Åström; Anna Sahlberg; Aino Fianu-Jonasson; Jérémie Gautier; Jean-Marc Costa; Bo Jacobsson; Kypros Nicolaides
Journal:  Prenat Diagn       Date:  2019-08-19       Impact factor: 3.050

4.  Validation of a SNP-based non-invasive prenatal test to detect the fetal 22q11.2 deletion in maternal plasma samples.

Authors:  Harini Ravi; Gabriel McNeill; Shruti Goel; Steven D Meltzer; Nathan Hunkapiller; Allison Ryan; Brynn Levy; Zachary P Demko
Journal:  PLoS One       Date:  2018-02-23       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.